JP Morgan Maintains Overweight on Zymeworks, Raises Price Target to $33

Benzinga Newsdesk www.benzinga.com Positive 82.3%

Neg 0% Neu 0% Pos 82.3%

JP Morgan analyst Brian Cheng maintains Zymeworks (NASDAQ:ZYME) with a Overweight and raises the price target from $31 to $33.